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Summary
AIMS OF THE STUDY: Although systemic drugs can exert
local effects on the eye, ophthalmology is a medical spe-
cialty with perhaps the fewest assessed adverse drug
reactions (ADRs), representing a particular challenge in
pharmacovigilance. Our aim was to quantify ADRs in oph-
thalmology in Switzerland, with a focus on angiogenesis
inhibitors.
METHODS: Individual case safety reports (ICSRs) on sus-
pected ADRs reported in Switzerland from January 1991
to June 2016 were extracted from the WHO Global ICSR
database, VigiBase™. ICSRs were analysed in relation
to treatment duration, patient age, route of administration,
patient sex and reported symptoms.
RESULTS: A total of 80,515 ICSRs were reported in
Switzerland during the reference period. Reactions linked
to eye disorders accounted for 2793 (3.5%) cases. The
main Anatomic Therapeutic Chemical / Defined Daily
Dose drug classes associated with eye disorders were
drugs acting on the nervous system (27.7%) followed by
drugs “acting on sensory organs” (20.2%) and antineo-
plastic agents (18.0%). Most cases involved adult patients
(70.6%). Patients over 60 years accounted for 815
(29.2%) ICSRs, and reactions in children were significant-
ly less frequent (8.2%). Older patients were exposed to
a higher number of drugs, and the majority of serious re-
actions involved children and older patients. A significant
positive correlation between polypharmacy and serious-
ness of reported reactions was observed. The reported
drugs were categorised as “suspected” in 51.1%, “con-
comitant” in 43.3% and “interacting” in 2.6% of cases. “Vi-
sual impairment” was the most commonly reported ad-
verse reaction, experienced by 635 (22.7%) of patients
(7.2% of all reported eye-related symptoms). The majority
of reactions were transient, as 4173 (47.1%) completely
resolved. Severe reactions included fatal outcome in 18
patients (0.6%) and blindness in 78 patients (2.6%). Since
2000, the intravitreous vascular endothelial growth factor
(VEGF) inhibitors bevacizumab, aflibercept and
ranibizumab accounted for 99 ICSRs. Retinal haemor-
rhage (reporting odds ratio [ROR] 10.36, 95% confidence
interval [95% CI] 2.65–40.50; p <0.001), blindness (ROR
3.73, 95% CI 1.08–12.96; p = 0.04) and uveitis (ROR 6.91,
95% CI 1.64–29.13; p = 0.01) were significantly more fre-
quently reported for aflibercept than for bevacizumab and
ranibizumab.
CONCLUSIONS: ADRs that affect the eye represented
3.5% of all pharmacovigilance reports during the reporting
period. Whereas retinal haemorrhage and uveitis are
known adverse reactions to angiogenesis inhibitors, the
reported cases of blindness and death should heighten
awareness of potential safety issues associated with
VEGF inhibitors for the treatment of proliferative eye dis-
orders.
Keywords: adverse drug reaction, adverse drug event,
macular degeneration, retinopathy, monoclonal antibody,
drug safety, patient safety, signal detection, disproportion-
ality analysis, pharmacoepidemiology
Introduction
Ophthalmology is one of the medical specialties for which
the fewest assessed adverse drug reactions (ADRs) have
been reported, which represents a particular challenge in
pharmacovigilance [1]. Numerous systemic drugs produce
adverse effects that can involve the eye. For example, an-
ticholinergic drugs such as antihistamines, tricyclic antide-
pressants, sleep aids or cold preparations can lead, among
other adverse reactions, to blurred vision and impaired sta-
bility in the upright position; patients under the influence
of these side effects thus have a tendency to fall [2]. How-
ever, topically applied ocular drugs may be systemically
absorbed to a significant extent, resulting in widespread
adverse side effects in both the eye and other regions of
the body [3]. In particular, new ocular drugs, such as vas-
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cular endothelial growth factor (VEGF) inhibitors, which
have increasingly been prescribed since their approval in
the middle of the last decade, are potentially related to nu-
merous systemic ADRs.
Several reports have indicated an association between oc-
ular ADRs and systemic drugs, but there have been only a
few systematic reviews to date [1]. With an increased focus
on the safety of these medications, however, more studies
are needed to reach further significant conclusions on sig-
nals emerging from retrospective studies. Ocular ADRs are
frequent and the majority of these events are innocuous for
the patients, although detrimental reactions, including fa-
tal ADRs and blindness, have been reported and need to
be effectively prevented to safeguard patients and reduce
strain on the health system. Visual impairment and blind-
ness are a considerable economic burden, which increases
with the degree of visual impairment, for affected persons,
their caregivers and society at large [4].
The use of anti-angiogenic therapy imposes potential risks
for ocular ADRs. VEGF inhibitors have revolutionised
the treatment of retinal disease with an impact on retinal
pathologies probably even greater than in oncology, but de-
spite the apparent safety of the small doses used for treat-
ing eye disease, these agents are highly potent [5]. Over
the past 15 years, a disproportionate increase in cardiovas-
cular and cerebrovascular events has been observed in pa-
tients treated with ranibizumab [5]. However, systematic
reviews have reported contradictory results, showing low
rates of reported serious adverse events after anti-VEGF
injections [6]. The incidence of blindness as an adverse
event is relevant; increased reporting of endophthalmitis
after the topical administration of bevacizumab was ob-
served [5], indicating a risk for this debilitating adverse ef-
fect. Although the prognosis for endophthalmitis has im-
proved significantly with advances in antibiotic treatment
and vitreoretinal surgery, the number of patients requiring
evisceration or enucleation remains significant [7]. Ther-
apeutic approaches using anti-VEGF medications thus re-
quire increased attention to safety.
Drugs in this class show diverse pharmacokinetics and
pharmacodynamics; for example, bevacizumab is more
likely than ranibizumab to induce immune activation and
to remain in the systemic circulation. Thus, bevacizumab
administration creates a higher risk of systemic adverse
events [8].
Current legislation in Switzerland compels any individual
who professionally dispenses or administers therapeutic
products to humans or animals to notify the Swiss Agency
for Therapeutic Products (Swissmedic) of any serious and
previously unknown ADRs or quality defects. Sponta-
neous reporting systems have an important role in the in-
vestigation of rare and unpredictable ADRs such as ad-
verse events in ophthalmology. In addition, the collection
of these data allows the early detection of ADRs in the
post‐marketing phase.
The aim of the present study was to quantify ADR reports
in ophthalmology in Switzerland by identifying frequen-
cies in spontaneous reports listed in a global database. Our
investigation sought to identify the number of cases in oc-
ular pharmacovigilance and to support the requirement for
ongoing surveillance and large population-based studies to
investigate these outcomes.
Materials and methods
Study design
This was a retrospective cohort study using registry data,
with a base cohort consisting of all ADRs associated with
the system organ class term “eye disorders” [1]. An impor-
tant focus of our analyses was new ocular drugs licensed in
Switzerland in the past 15 years, the majority of which are
anti-VEGF agents approved in Switzerland since the mid-
dle of the last decade. We reviewed individual case safe-
ty reports (ICSRs) submitted in Switzerland between Janu-
ary 1991 and June 2016. ADRs were analysed with respect
to reporting rate per year, age and sex of the patient, and
reported symptoms. Patients were grouped based on their
age by decade and reported symptoms were described ac-
cording to MedDRA terminology.
Data source
ICSRs were obtained using the online software Vigi-
Lyze™, which allows registered users to access data from
VigiBase™, the world’s largest spontaneous ADR system,
with more than 8.4 million reports from 104 countries
compiled since the WHO international drug monitoring
programme started in 1968 [9]. VigiLyze™ allows users to
examine data on ADRs using various filters to facilitate da-
ta acquisition and to download additional information on
the ICSRs. VigiBase™ is a registry database with no ac-
cess to clinical or laboratory data. Therefore, the causal re-
lationship between drug and ADR could not be no formal-
ly assessed [10].
Data adjustment
Many data were adjusted for the statistical analysis, for ex-
ample by removing redundancy and bringing the variables
into alignment – such as by avoiding repeated terms and
synonyms – thus promoting an unambiguous interpretation
of the available information while retaining the original
content of the report. Duplicate records were also system-
atically removed. A relevant number of ADR reports in-
cluded only an approximate duration of the event. Where
only the month and year of the start or stop of an ADR
were reported, we counted the indicated month as a full
month. Where only the year was indicated, we excluded
the corresponding ADR from the analysis of event dura-
tion, indicating it as “unknown”. A similar approach was
adopted by Blaser et al. [11] in an analogous study. A sim-
ilar readjustment was performed in relationship to the in-
dividual reporting the single ADR to the authority: when
more than one individual was indicated as reporter, only
the most competent was considered for the analysis. For
example, when a physician and a layman were listed as re-
porters of the same ADR, only the former was taken into
account. While aligning the fields related to the outcomes
of the ADRs, only the term pertaining to the most disabling
condition – in accordance with the seriousness criteria of
the event – was considered.
Polypharmacy is not unequivocally defined in the scientif-
ic literature. In our study, we applied the most commonly
used definition for polypharmacy, namely the condition of
taking five or more medications daily [12]. Missing data or
data insufficiently itemised to allow correct categorisation
were classified as “unknown” and represented an indepen-
dent statistical category.
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Statistical analysis
Descriptive statistics were used to summarise and describe
the data. The linear correlation between the number of
drugs and the rate of serious ADRs was established as the
coefficient of determination and was highest when the da-
ta were plotted on a simple linear regression model. Re-
porting odds ratios (RORs), seen as the pharmacovigilance
equivalent of the odds ratio (OR), 95% confidence inter-
val (CIs), and p-values were calculated to measure dispro-
portionality for drug-reaction pairs, comparing each of the
three anti-VEGF drugs with the other two [13]. Fisher’s
exact test was used as a nonparametric statistical test of the
null hypothesis that no associations existed between two
different RORs as categorical variables against the alterna-
tive hypothesis that there was an association between the
variables. Values of p <0.05 were considered significant.
All statistical analyses were performed using SPSS Sta-
tistics (developed by IBM, Armonk (NY), version 25.0
(2017), software package for Mac) and MATLAB (devel-
oped by MathWorks, Natick (MA), version R2017b, soft-
ware package for Mac).
Results
Overview and flow chart
ICSRs associated with eye disorders reported in Switzer-
land from January 1991 to June 2016 were selected from
the WHO VigiBase. Following data adjustment and the re-
moval of duplicates, we obtained 2793 ICSRs correspond-
ing to 6521 drug-reaction pairs (fig. 1). Ocular adverse re-
actions constituted a small proportion (3.5%) of all ICSRs
reported in Switzerland during the period of interest (to-
tal number of reports 80,515). Nevertheless, underreport-
ing could be an important limitation of spontaneous report-
ing systems for ADRs such as the WHO VigiBase, leading
to biased data and possibly false conclusions.
Most frequently implicated drugs and drug-reaction
pairs
The main Anatomic Therapeutic Chemical / Defined Daily
Dose (ATC/DDD) drug group associated with eye disor-
ders comprised medications acting on the nervous system
(ATC/DDD class N), with 774 (27.7%) ICSRs attributed to
this drug class. This was followed by 563 (20.2%) ICSRs
associated with drugs acting on sensory organs (ATC/DDD
class S), 503 (18.0%) representing antineoplastic agents
(ATC/DDD class L), and 390 (14.0%) representing derma-
tological medications (ATC/DDD class D).
Table 1 lists two binary variables, polypharmacy and se-
riousness of the adverse reaction, and shows their asso-
ciation with the medications described in the ICSRs, the
gender and age of patients, and the qualification of the in-
dividual who reported the adverse reaction. The ten listed
medications were the most frequently reported, regardless
of the relationship between medication and ADR (sus-
pected, concomitant or interacting). Taken together, these
drugs accounted for 773 (27.7%) drug-reaction pairs,
among which the most frequently reported ATC/DDD drug
group denoted the trend for all reports, with 40% of drugs
acting on the nervous system.
The majority of cases involved adult patients (70.6%): pa-
tients aged over 60 years accounted for 815 (29.2%) ICSRs
whereas reactions reported in children were significantly
less frequent (8.2%). An analysis of patient age revealed
Figure 1: Flow chart showing the systematic processes adopted to achieve the final data sample.
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an interesting U-shaped correlation with the seriousness of
the adverse drug reaction: children and older patients were
more likely to experience serious events than adult patients
aged 20–70 years. A similar trend was not observed for the
frequency of multidrug therapy: in general, older patients
appeared to be exposed to a larger number of medications
than younger patients. The only exception to this observa-
tion was small children aged under 10 years, who had sim-
ilar values to patients aged 60–80 years (26.4%).
Health professionals were the main reporters, associated
with three out of four ICRSs (75.2%). Overall, physicians
had higher reporting rates for ADRs evaluated as serious
(57.5%) compared with lay consumers (42.9%).
Given the prevalence of patients receiving several drugs si-
multaneously, we performed a statistical analysis to inves-
tigate the correlation between the number of concurrently
ingested drugs and the seriousness of ADRs in the affect-
ed patients (fig. 2). The majority of ICSRs pertained to pa-
tients who had taken a single drug (1326 ICSRs). In this
group of patients, only 576 (43.4%) ICSRs were assessed
as serious. This percentage increased linearly: for five con-
currently ingested drugs – the definition of polypharmacy
– it reached 49.6% of serious ICSRs and for nine concur-
rently ingested drugs, it reached a maximum, with three
out of four ICSRs assessed as serious (75.0%). Our sta-
tistical analysis included up to 10 concurrently ingested
drugs, as beyond this number the proportion of ICSRs in
each group was insufficient to allow a consistent analysis,
showing a reverse trend. This may be due to statistical bias
caused by the small number of patients included and the
non-representative population sample.
Table 2 displays the analysis of causal relationships be-
tween drugs and adverse reactions using data derived from
the ICSRs as variables. A suspected relationship between
drug and event was identified for half of the drug-reaction
pairs (51.1%). Of the remaining pairs, most were assessed
as concomitant (43.3%), with only a few classified as in-
Figure 2: Linear correlation between number of concurrent ingest-
ed medications and rate of serious ADRs
Table 1: Number and percentage of cases associated with polypharmacy and serious events, by name of implicated drug, sex and age of the patient, and qualification of the re-
porting figure.
Total cases Polypharmacy Serious ADR
n % Yes No Yes No
n % n % n % n %
Name of the
drug
Acetylsalicylic acid 147 5.3% 46 31.3% 101 68.7% 21 14.3% 17 11.6%
Paracetamol 90 3.2% 35 38.9% 55 61.1% 22 24.4% 10 11.1%
Lorazepam 78 2.8% 33 42.3% 45 57.7% 15 19.2% 9 11.5%
Venlafaxine 73 2.6% 52 71.2% 21 28.8% 13 17.8% 21 28.8%
Pantoprazole 72 2.6% 27 37.5% 45 62.5% 13 18.1% 5 6.9%
Ranibizumab 57 2.0% 52 91.2% 5 8.8% 38 66.7% 4 7.0%
Fingolimod 67 2.4% 59 88.1% 8 11.9% 53 79.1% 12 17.9%
Atorvastatin 66 2.4% 29 43.9% 37 56.1% 5 7.6% 8 12.1%
Latanoprost 64 2.3% 58 90.6% 6 9.4% 29 45.3% 20 31.3%
Mirtazapine 59 2.1% 33 55.9% 26 44.1% 8 13.6% 8 13.6%
Sex of the pa-
tient
Male 990 35.4% 163 16.5% 827 83.5% 469 47.4% 309 31.2%
Female 1651 59.1% 279 16.9% 1372 83.1% 756 45.8% 587 35.6%
Unknown 152 5.4% 5 3.3% 147 96.7% 77 50.7% 62 40.8%
Age of the pa-
tient (years)
0–9 91 3.3% 24 26.4% 67 73.6% 56 61.5% 23 25.3%
10–19 138 4.9% 11 8.0% 127 92.0% 76 55.1% 33 23.9%
20–29 197 7.1% 17 8.6% 180 91.4% 74 37.6% 68 34.5%
30–39 260 9.3% 27 10.4% 233 89.6% 109 41.9% 84 32.3%
40–49 365 13.1% 53 14.5% 312 85.5% 175 47.9% 112 30.7%
50–59 336 12.0% 54 16.1% 282 83.9% 154 45.8% 121 36.0%
60–69 366 13.1% 91 24.9% 275 75.1% 157 42.9% 130 35.5%
70–79 310 11.1% 91 29.4% 219 70.6% 168 54.2% 90 29.0%
80–89 132 4.7% 42 31.8% 90 68.2% 80 60.6% 32 24.2%
90–99 6 0.2% 3 50.0% 3 50.0% 4 66.7% 2 33.3%
100+ 1 0.04% 0 0.0% 1 100.0% 0 0.0% 1 100.0%
Unknown 591 21.2% 189 32.0% 402 68.0% 242 40.9% 258 43.7%
Reporter qualifi-
cation
Consumer 245 8.8% 25 10.2% 220 89.8% 105 42.9% 140 57.1%
Physician 1692 60.6% 326 19.3% 1366 80.7% 973 57.5% 526 31.1%
Pharmacist 217 7.8% 37 17.1% 180 82.9% 107 49.3% 110 50.7%
Lawyer 2 0.1% 0 0.0% 2 100.0% 2 100.0% 0 0.0%
Other health professional 162 5.8% 16 9.9% 146 90.1% 63 38.9% 98 60.5%
Other 203 7.3% 0 0.0% 190 93.6% 0 0.0% 0 0.0%
Unknown 272 9.7% 30 11.0% 242 89.0% 105 38.6% 84 30.9%
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teracting (2.6%). The duration of ADRs was not normally
distributed, shorter ADRs being significantly more preva-
lent than longer reactions. The range between the shortest
and the longest ADR was from 1 day to several years, with
a median duration of about 8 days. These data have to be
interpreted with caution as only 27.8% of the drug-reaction
pairs provided relevant data.
Most frequent reactions and principle outcomes
In addition to evaluating the most frequently implicated
medications and their relationship with the ICSRs, we as-
sessed the most common types of ADR. From a total of
8865 different reported reactions and 2793 ICSRs notified,
each patient presented with an average of 3.17 symptoms.
A total of 635 (22.7%) patients experienced “visual im-
pairment” after medication; this was the symptom most
commonly reported and constituted 7.2% of all reported
symptoms. This was followed by “eyelid oedema” in 206
patients (7.4%), “vision blurred” in 201 patients (7.2%),
“diplopia” in 158 patients (5.7%), “eye irritation” in 128
patients (4.6%), “mydriasis” in 121 patients (4.3%) “eye
pain” in 112 patients (4.0%), “ocular hyperaemia” in 91
patients (3.3%), “periorbital oedema” in 78 patients
(2.8%), and “dry eye” in 63 patients (2.3%). Less frequent
but highly relevant ADRs included fatal reactions, with
death reported for 18 (0.6%) patients, and “blindness” for
73 (2.6%) patients.
The majority of reactions were temporary, as 4173 (47.1%)
resolved completely. One in every three resolved reactions
did not resolve completely: 1321 (14.9%) reactions were
permanent and 106 (1.2%) led to long-term sequelae. For
669 (7.5%) reactions, resolution was ongoing, and for
more than one in four reactions the outcome could not be
determined because of missing data (28.7%).
The best prognosis was observed for mydriasis, as 58
(71.1%) reactions were completely resolved. Other com-
mon reactions with particularly positive outcomes were
periorbital oedema (62.8%), eyelid oedema (62.1%) and
diplopia (53.1%). However, we also identified recurring
reactions with outcomes that were frequently negative. For
Table 2: Characterisation of the causal relationship between drug and reaction for the different ICSRs sorted by involved medication, duration of the ADR, drug’s route of admin-
istration and drug’s indication.
Total cases Characterisation
n % Suspected Concomitant Interacting
n % n % n %
Name of the drug Acetylsalicylic acid 147 2.3% 33 22.4% 109 74.1% 5 3.4%
Paracetamol 92 1.4% 27 29.3% 61 66.3% 4 4.3%
Lorazepam 79 1.2% 33 41.8% 44 55.7% 2 2.5%
Venlafaxine 73 1.1% 45 61.6% 27 37.0% 1 1.4%
Pantoprazole 72 1.1% 28 38.9% 43 59.7% 1 1.4%
Fingolimod 67 1.0% 51 76.1% 14 20.9% 2 3.0%
Atorvastatin 66 1.0% 30 45.5% 35 53.0% 1 1.5%
Latanoprost 65 1.0% 48 73.8% 16 24.6% 1 1.5%
Mirtazapine 61 0.9% 20 32.8% 40 65.6% 1 1.6%
Esomeprazole 59 0.9% 35 59.3% 24 40.7% 0 0.0%
Duration of the
ADR
1 day 528 7.9% 438 83.0% 77 14.6% 13 2.5%
2 days 119 1.8% 88 73.9% 25 21.0% 6 5.0%
3 days 79 1.2% 59 74.7% 16 20.3% 4 5.1%
4 days 49 0.7% 35 71.4% 11 22.4% 3 6.1%
5 days 38 0.6% 33 86.8% 5 13.2% 0 0.0%
6 days 48 0.7% 36 75.0% 10 20.8% 2 4.2%
7 days 41 0.6% 35 85.4% 6 14.6% 0 0.0%
8 days 43 0.6% 33 76.7% 10 23.3% 0 0.0%
Route of drug ad-
ministration
Enteral 3170 48.6% 1669 52.6% 1351 42.6% 150 4.7%
Parenteral 798 12.2% 635 79.6% 152 19.0% 11 1.4%
Topical ocular 373 5.7% 336 90.1% 36 9.7% 1 0.3%
Respiratory 60 0.9% 23 38.3% 37 61.7% 0 0.0%
Topical (not on the eye) 57 0.9% 46 80.7% 11 19.3% 0 0.0%
Unknown 481 7.4% 287 59.7% 193 40.1% 1 0.2%
No data 1582 24.3% 442 27.9% 1126 71.2% 14 0.9%
Drug indication Depressive episode or disorder 119 1.8% 82 68.9% 18 15.1% 19 16.0%
Essential hypertension 113 1.7% 53 46.9% 59 52.2% 1 0.9%
Glaucoma 92 1.4% 86 93.5% 6 6.5% 0 0.0%
Osteoporosis 52 0.8% 37 71.2% 15 28.8% 0 0.0%
Epilepsy 57 0.8% 35 61.4% 15 26.3% 7 12.3%
Diabetes 43 0.6% 19 44.2% 24 55.8% 0 0.0%
Multiple sclerosis 69 1.0% 67 97.1% 2 2.9% 0 0.0%
Migraine 39 0.6% 28 71.8% 11 28.2% 0 0.0%
Asthma 30 0.4% 12 40.0% 17 56.7% 1 3.3%
Disorder of lipid metabolism 28 0.4% 18 64.3% 10 35.7% 0 0.0%
Unknown 226 3.4% 98 43.4% 128 56.6% 0 0.0%
No data 3830 57.0% 1586 41.4% 2165 56.5% 79 2.1%
Original article Swiss Med Wkly. 2019;149:w20085
Swiss Medical Weekly · PDF of the online version · www.smw.ch
Published under the copyright license “Attribution – Non-Commercial – No Derivatives 4.0”.
No commercial reuse without permission. See http://emh.ch/en/services/permissions.html.
Page 5 of 9
example, one out of five reactions leading to visual impair-
ment did not recover (21.1%), and for dry eye 18 (28.6%)
reactions were permanent.
Most frequent reactions and ADRs comparison among
VEGF inhibitors
VEGF inhibitors are approved in Switzerland for the treat-
ment of diseases affecting the eye that have neovascu-
larisation as the main pathophysiological mechanism. At
present, three VEGF inhibitors account for the majority
of ocular disorders notified in Switzerland since their ap-
proval: of a total of 99 (3.5%) ICSRs reported, 57 (57.6%)
represented patients treated with ranibizumab, 33 (33.3%)
with aflibercept and 10 (10.1%) with bevacizumab. The
first ICSRs pertaining to VEGF inhibitors were reported
in 2006, but most ADRs were reported between 2012 and
2016 (76 ICSRs corresponding to 76.8% of patients).
An increasing trend was observed in relation to patient age:
for every ICSR reported for a child aged under 2 years,
45 were reported for patients older than 65 years. Female
patients were more likely to experience adverse events in-
volving anti-neovascularisation agents: 55.6% of ICSRs
concerned women and only 17.2% involved male patients.
Table 3 lists the most common reactions reported in asso-
ciation with each of the three cited VEGF inhibitors. A to-
tal of 159 reactions were notified, comprising 106 (66.7%)
related to ranibizumab, 42 (26.4%) to aflibercept and 11
(6.9%) to bevacizumab. For bevacizumab, all reactions are
listed; for the other two medications, only the 15 most fre-
quently recurring terms are reported.
Table 4 shows a disproportionality analysis for the intrav-
itreal application of ranibizumab, aflibercept, and beva-
cizumab. Reporting odds ratio (ROR), confidence inter-
val (CI), and p-value were calculated for each single drug
compared with the other two medications considered as
a unique category. For ranibizumab, only an inverse sig-
nificant disproportionality (ROR <1.00) was identified in
connection with retinal haemorrhage (ROR 0.14, 95% CI
0.04–0.55; p = 0.005) and uveitis (ROR 0.13, 95% CI
0.03–0.63; p = 0.012), meaning that ranibizumab proba-
bly confers less risk for these reactions as compared with
aflibercept and bevacizumab. Bevacizumab showed a sig-
nificant disproportionality for visual impairment (ROR
4.67, 95% CI 1.08–20.16; p = 0.04), and no other ROR
showed a significant correlation with the respective data.
Aflibercept showed the greatest number of significantly
disproportional RORs: retinal haemorrhage (ROR 10.36,
95% CI 2.65–40.50; p <0.001), blindness (ROR 3.73, 95%
CI 1.08–12.96; p = 0.04), and uveitis (ROR 6.91, 95% CI
1.64–29.13; p = 0.01) were significantly more frequently
reported in association with aflibercept than with the other
two VEGF inhibitors.
Discussion
A total of 8865 different reactions affecting the eye were
reported within the period under consideration. The major-
ity of cases involved adult patients and the main class of
drugs associated with ocular ADRs were those acting on
the nervous system. Health professionals were the main re-
porters of the ADRs and the majority of ICSRs pertained
to patients who had ingested a single drug. A suspected re-
lationship between drug and event was identified for half
of the drug-reaction pairs (51.1%). The range between the
shortest and the longest ADR was from 1 day to several
years, with a median duration of about 8 days. The major-
ity of reactions were temporary, as 4173 (47.1%) resolved
completely. Visual impairment was the most commonly re-
ported reaction and constituted 7.2% of all reported symp-
toms. Analysis of the association of VEGF inhibitors as
a single class of drugs with ocular ADRs indicated that
aflibercept was positively associated with serious ocular
ADRs such as blindness, retinal haemorrhage and uveitis.
Although ADRs affecting the eye appear only in 3 of 100
patients reporting any adverse event, drug-induced ocu-
lar events are the second most common reason for official
complaints against ophthalmologists [14]. Ocular ADRs
primarily manifest as visual impairment, which, as an ad-
verse side-effect of medication, is rare but can lead to con-
siderable individual and societal burdens, and the acquisi-
tion of robust data to identify and confirm the relationship
between a medication and an uncommon adverse side-ef-
fect is challenging [15]. As serious ADRs, blindness and
lethal reactions constituted only a small part of the total
reported ICSRs, although the real incidence of such cases
Table 3: Number and percentage of the first 15 most reported ADRs for ranibizumab, aflibercept und bevacizumab.
Ranibizumab (n = 106) Aflibercept (n = 42) Bevacizumab (n = 11)
ADR n % ADR n % ADR n %
Eye pain 10 9.4% Retinal haemorrhage 9 21.4% Visual impairment 3 27.3%
Visual impairment 10 9.4% Blindness 6 14.3% Blepharitis 1 9.1%
Visual acuity reduced 7 6.6% Uveitis 6 14.3% Blindness transient 1 9.1%
Eye inflammation 5 4.7% Retinal disorder 4 9.5% Iridocyclitis 1 9.1%
Retinal disorder 5 4.7% Retinal pigment epithelial tear 3 7.1% Keratitis 1 9.1%
Blindness 4 3.8% Non-infectious endophthalmitis 2 4.8% Retinal artery embolism 1 9.1%
Retinal vein thrombosis 4 3.8% Anterior chamber disorder 1 2.4% Uveitis 1 9.1%
Vitreous disorder 4 3.8% Cataract 1 2.4% Vision blurred 1 9.1%
Vitreous floaters 4 3.8% Eye irritation 1 2.4% Vitreous detachment 1 9.1%
Vitreous haemorrhage 4 3.8% Eye pain 1 2.4%
Eye oedema 3 2.8% Iridocyclitis 1 2.4%
Ocular hyperaemia 3 2.8% Photophobia 1 2.4%
Ocular hypertension 3 2.8% Pseudoendophthalmitis 1 2.4%
Retinal haemorrhage 3 2.8% Visual acuity reduced 1 2.4%
Eye irritation 2 1.9% Visual impairment 1 2.4%
Total 71 67.0% Total 39 92.9% Total 11 100.0%
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may be greater as ADRs in ophthalmology are a hetero-
geneous group that are not commonly detected [5]. This
assumption underscores the importance of ophthalmolo-
gists’ awareness of specific ocular ADRs related to sys-
temic medication and how to detect and adequately treat
these ADRs as part of good clinical practice [5].
Certain sub-populations appear to be more susceptible to
ocular adverse reactions. Frail patients are more likely to
be exposed to polypharmacy [16], which may increase the
risk of inappropriate drug use and ADRs [17]. Our analysis
supports these findings, as the percentage of serious ADRs
was significantly correlated with the number of ingested
medications and with patient age. A previous meta-analy-
sis of the relationship between systemic fluoroquinolones
and retinal detachment did not show any significant asso-
ciation [18]. In our data we found 26 cases of retinal de-
tachment and only one case (3.85%) was associated with
the intake of fluoroquinolones, supporting the conclusion
of the meta-analysis.
Interesting differences were observed with respect to drugs
used to prevent angiogenesis. Our data indicate that
aflibercept was positively associated with serious ocular
ADRs such as blindness, retinal haemorrhage and uveitis.
These results were based on very small numbers: six cases
of blindness with aflibercept and four with ranibizumab
(see table 3). In contrast, bevacizumab showed a signif-
Table 4: Main ADRs for ranibizumab, bevacizumab, and aflibercept, with reporting odds ratio, 95% confidence intervals, and p-value against the other two drugs.
Comparison ADR ROR 95% CI p-value
Ranibizumab versus aflibercept
and bevacizumab
Eye pain 5.42 0.67–43.50 0.11
Visual impairment 1.28 0.38–4.28 0.69
Visual acuity reduced 3.68 0.44–30.69 0.23
Retinal disorder 0.61 0.16–2.36 0.47
Blindness 0.45 0.15–1.36 0.16
Vitreous floaters 2.04 0.22–18.71 0.53
Vitreous haemorrhage 2.04 0.22–18.71 0.53
Retinal haemorrhage 0.14 0.04–0.55 0.005
Uveitis 0.13 0.03–0.63 0.012
Eye irritation 1.00 0.09–11.29 1.00
Anterior chamber disorder 0.50 0.03–8.08 0.61
Photofobia 0.50 0.03–8.08 0.61
Pseudoendophthalmitis 0.50 0.03–8.08 0.61
Vitritis 0.50 0.03–8.08 0.61
Iridocyclitis 0.16 0.00–4.10 0.27
Vision blurred 0.16 0.00–4.10 0.27
Aflibercept versus ranibizumab
and bevacizumab
Retinal haemorrhage 10.36 2.65–40.50 <0.001
Blindness 3.73 1.08–12.96 0.04
Uveitis 6.91 1.64–29.13 0.01
Retinal disorder 2.36 0.60–9.24 0.22
Anterior chamber disorder 2.83 0.17–46.28 0.47
Eye pain 0.26 0.03–2.10 0.21
Iridocyclitis 2.83 0.17–46.28 0.47
Photophobia 2.83 0.17–46.28 0.47
Pseudoendophthalmitis 2.83 0.17–46.28 0.47
Visual acuity reduced 0.38 0.05–3.21 0.38
Vitreous floaters 0.69 0.07–6.35 0.74
Vitreous haemorrhage 0.69 0.07–6.35 0.74
Vitritis 2.83 0.17–46.28 0.47
Visual impairment 0.20 0.02–1.54 0.12
Vision blurred 0.54 0.03–11.55 0.70
Eye irritation 0.54 0.03–11.55 0.70
Bevacizumab versus ranibizumab
and aflibercept
Visual impairment 4.67 1.08–20.16 0.04
Blindness 1.38 0.16–11.89 0.77
Iridocyclitis 7.30 0.61–87.57 0.12
Uveitis 1.75 0.20–15.41 0.61
Vision blurred 14.70 0.85–252.84 0.06
Eye pain 0.52 0.03–9.40 0.66
Visual acuity reduced 0.72 0.04–13.26 0.82
Retinal disorder 0.64 0.03–11.68 0.76
Vitreous floaters 1.13 0.06–21.82 0.93
Vitreous haemorrhage 1.13 0.06–21.82 0.93
Retinal haemorrhage 0.47 0.03–8.54 0.61
Eye irritation 1.81 0.09–37.17 0.70
Anterior chamber disorder 2.55 0.12–56.28 0.55
Photofobia 2.55 0.13–56.28 0.55
Pseudoendophthalmitis 2.55 0.13–56.28 0.55
Vitritis 2.55 0.13–56.28 0.55
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icant inverse association with both retinal haemorrhage
and uveitis. An Australian case report on uveitis following
the use of intravitreal aflibercept also cautions clinicians
to be aware of late-onset sterile uveitis and vitritis after
aflibercept injection [19]. Conversely, a double-blind ran-
domised controlled trial showed that aflibercept was as-
sociated with similar visual and anatomic outcomes as
ranibizumab when dosed monthly, as well as similar safety
and tolerability [20].
Further research is required to investigate the culpability of
VEGF inhibitors in serious eye disorders. The limited lit-
erature on this issue may be the main ascribable circum-
stance, but also the erroneous conduct and technique of ad-
ministering intravitreal drugs may play a crucial role. One
study showed that vision loss was not the result of the drug
itself or the injection technique, but rather of the proce-
dures used to prepare the syringes containing bevacizumab
[21].
Pharmacovigilance studies based on spontaneous reporting
have several limitations, including under- and selective re-
porting [22], and our findings should be interpreted in this
context. Many ICSRs had missing data or data that were
only partially specified; these circumstances, when applied
to large datasets, can contribute to increased uncertainty
surrounding the available information. Another limitation
is the multiple comparison issue (the propensity to gen-
erate false positive results as the number of comparisons
increases) considered endemic in the analysis of sponta-
neous reporting databases [23]. The voluntary nature of
the reports also creates inherent limitations in data inter-
pretation, and population differences across the participat-
ing countries have not been accounted for in the present
study. In addition, clinical information contained in a spon-
taneous reporting database such as the WHO VigiBase is
necessarily limited and cases can be reported more than
once. However, our method allowed us to eliminate as
many potential duplicate records as possible [8]. Finally,
causality assessment was frequently not reported in the re-
trieved records [24].
Our findings highlight the importance of the routine de-
tection of adverse reactions by physicians and other health
professionals. Failure to recognise an ADR may result in
a prescribing cascade whereby a new drug is administered
to treat the adverse effect of the culprit drug, thus exposing
the patient to a continued risk of an ADR from the culprit
drug and additional risks from the newly prescribed drug
[25]. To promote reporting of ocular ADRs, the awareness
of both ophthalmologists and other practitioners of the risk
of such ADRs could be increased by introducing routine
pharmacovigilance activities into daily practice or by en-
hancing education in pharmacovigilance at both the under-
and postgraduate level.
In conclusion, ocular ADRs in Switzerland may be more
common than the number reported by health professionals
suggests, implying that a more meticulous approach is
required to detect serious ADRs. Serious adverse events
are frequently overlooked because they are more common
when polypharmacy is present, increasing the effort need-
ed to determine whether a single drug is more likely to
cause a specific ADR than the other medications. Although
our data indicate that aflibercept was more significantly as-
sociated with serious ocular ADRs than other VEGF in-
hibitors, care is required in the use of this class of drugs be-
cause of the lack of relevant literature and risk of improper
drug administration, leading to biased results.
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